Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development.
Patrono
C
C
Department of Pharmacology, University of Chieti G. D'Annunzio School of Medicine, Italy.
Patrignani
P
P
Rocca
B
B
Landolfi
R
R
D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017322:Clinical Trials, Phase II as Topic; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D009391:Nephelometry and Turbidimetry; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D013928:Thromboxane A2 / Q000096:biosynthesis; D013929:Thromboxane B2 / Q000652:urine; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors
D016861:Cyclooxygenase Inhibitors; D004791:Enzyme Inhibitors; D010975:Platelet Aggregation Inhibitors; D013929:Thromboxane B2; D013928:Thromboxane A2; D013930:Thromboxane-A Synthase; D001241:Aspirin